FDA Fast-Tracks Liquidia Drug for Painful Systemic Sclerosis Complication
Liquidia stock rises after the FDA grants Fast Track status to YUTREPIA for treating Raynaud’s phenomenon in systemic sclerosis.
Stocks · News reference
Wells Fargo Maintains Overweight on Liquidia, Raises Price Target to $108
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Overweight and raises the price target from $62 to $108.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Liquidia Corp (LQDA)
Filed: 2026-09-03 AccNo: 0001104659-26-104929 Size: 215 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Liquidia Receives FDA's Fast Track Designation For YUTREPIA Inhalation Powder To Treat Raynaud's Phenomenon Associated With Systemic Sclerosis
Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that the U.S. Food
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia Corporation's lead drug Yutrepia generated $300.3 million in first-half 2026 sales, driving the company's fourth consecutive profitable quarter. However, the pulmonary arterial hypertension (PAH) market faces intense competition from established therapies and pipeline candidates from United Therapeutics and Insmed. Liquidia plans to expand Yutrepia into additional indications including COPD, IPF, PPF, and Raynaud's phenomenon to sustain long-term growth.